Skip to main content
Boryung Corporation logo

Boryung Corporation — Investor Relations & Filings

Ticker · 003850 ISIN · KR7003850005 KO Manufacturing
Filings indexed 351 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 003850

About Boryung Corporation

https://pharm.boryung.co.kr/eng/index.do

Boryung Corporation is a fully integrated healthcare company founded in 1957. Its core business encompasses the research, development, manufacturing, and global commercialization of pharmaceutical products, with a significant presence in the cardiovascular therapeutic area. The company is distinguished by its pioneering 'Care in Space' (CIS) initiative, which focuses on developing healthcare solutions for humans in extreme environments and leveraging space for new research opportunities. In addition to its pharmaceutical operations, Boryung functions as a healthcare investment company, fostering innovation across the health sector. The company's diverse portfolio includes prescription drugs, over-the-counter products, and a pipeline aimed at addressing future medical needs.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is titled “분기보고서” (Quarterly Report) for the period 2026-01-01 to 2026-03-31, containing detailed company overview, business description, consolidated financial statements, notes, management analysis, audit opinion, and extensive financial tables. It is a full interim/quarterly report with actual financial data, not merely an announcement or summary. This fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
주식등의대량보유상황보고서(일반)
Regulatory Filings
2026-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-06 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Regulatory Filings
2026-04-30 Korean
공정거래자율준수프로그램운영현황(안내공시)
Regulatory Filings Classification · 82% confidence The document is a Korean stock exchange disclosure titled “공정거래 자율준수프로그램 운영현황(안내공시)” describing the compliance program’s 2025 H2 performance and 2026 H1 plan. It is a regulatory announcement (안내공시) of operational results and plans, not a financial report, earnings release, board change, dividend, share transaction, or other specific filing type. Therefore it falls under the general Regulatory Filings category.
2026-04-06 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.